control in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results UKHSA report week 12 (24 March 2022), 2022 (REV) 2.22 [0.95; 5.17]
2.22 [0.95 ; 5.17 ] UKHSA report week 12 (24 March 2022), 2022 (REV) 1 0% NA not evaluable deaths (time to event analysis only)detailed results UKHSA report week 12 (24 March 2022), 2022 (REV) 2.22 [0.95; 5.17]
2.22 [0.95 ; 5.17 ] UKHSA report week 12 (24 March 2022), 2022 (REV) 1 0% NA not evaluable clinical deteriorationdetailed results Lauring, 2022 (REV) 2.27 [1.94; 2.67]
2.27 [1.94 ; 2.67 ] Lauring, 2022 (REV) 1 0% 11,690 NA not evaluable confirmed COVID (any severity)detailed results England (Andrews), 2021 (REV) 1.94 [1.32; 2.86]
South Africa (Discovery Health, Collie), 2021 (REV) 2.00 [1.53; 2.62]
Southern California (Tseng) - omicron, 2022 (REV) 1.44 [1.05; 1.96]
Tenforde, 2022 (REV) 5.56 [4.33; 7.12]
Thompson -VISIOn Network (omicron), 2022 (REV) 2.08 [1.84; 2.36]
2.32 [1.51 ; 3.55 ] England (Andrews), 2021 (REV), South Africa (Discovery Health, Collie), 2021 (REV), Southern California (Tseng) - omicron, 2022 (REV), Tenforde, 2022 (REV), Thompson -VISIOn Network (omicron), 2022 (REV) 5 93% 138,105 NA not evaluable hospitalizationdetailed results Lauring, 2022 (REV) 6.67 [5.44; 8.16]
South Africa (Discovery Health, Collie), 2021 (REV) 3.33 [2.65; 4.19]
Thompson -VISIOn Network (omicron), 2022 (REV) 5.26 [2.81; 9.85]
4.86 [2.86 ; 8.26 ] Lauring, 2022 (REV), South Africa (Discovery Health, Collie), 2021 (REV), Thompson -VISIOn Network (omicron), 2022 (REV) 3 90% 11,690 NA not evaluable symptomatic Covid-19detailed results England (Andrews), 2021 (REV) 1.94 [1.32; 2.86]
Kirsebom (UKHSA), 2022 (REV) 1.32 [1.26; 1.39]
South Africa (Discovery Health, Collie), 2021 (REV) 2.00 [1.53; 2.62]
Thompson -VISIOn Network (omicron), 2022 (REV) 2.08 [1.84; 2.36]
1.79 [1.30 ; 2.44 ] England (Andrews), 2021 (REV), Kirsebom (UKHSA), 2022 (REV), South Africa (Discovery Health, Collie), 2021 (REV), Thompson -VISIOn Network (omicron), 2022 (REV) 4 94% 131,448 NA not evaluable 0.5 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-12 15:03 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 89
- treatments: 649,650,589,651,968
- roots T: 290
